India issues urgent public health notice for all GLP-1 drugs including semaglutide
The IPC has called for close monitoring of adverse reactions to semaglutide and other GLP-1 medications amid rising usage. Authorities emphasize post-marketing surveillance to identify side-effects and ensure safety for patients using these popular diabetes and weight-loss therapies.
Original Source
Read the full article at Livemint →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.